title: TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant.
abstract: The identification of cytokine adjuvants capable of inducing an efficient mucosal immune response against viral pathogens has been long anticipated. Here, we attempted to identify the potential of tumor necrosis factor superfamily (TNFS) cytokines to function as mucosal vaccine adjuvants. Sixteen different TNFS cytokines were used to screen mucosal vaccine adjuvants, after which their immune responses were compared. Among the TNFS cytokines, intranasal immunization with OVA plus APRIL, TL1A, and TNF-alpha exhibited stronger immune response than those immunized with OVA alone. TL1A induced the strongest immune response and augmented OVA-specific IgG and IgA responses in serum and mucosal compartments, respectively. The OVA-specific immune response of TL1A was characterized by high levels of serum IgG1 and increased production of IL-4 and IL-5 from splenocytes of immunized mice, suggesting that TL1A might induce Th2-type responses. These findings indicate that TL1A has the most potential as a mucosal adjuvant among the TNFS cytokines.
authors.affiliation: Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation (NiBio), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kayamuro
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Abe
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Katayama
authors.forename: Tokuyuki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Kohei
authors.initials: K
authors.lastname: Yamashita
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Takachika
authors.initials: T
authors.lastname: Hiroi
authors.forename: Norio
authors.initials: N
authors.lastname: Itoh
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kawai
authors.forename: Tadanori
authors.initials: T
authors.lastname: Mayumi
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Kamada
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Tsunoda
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tsutsumi
mesh_terms: D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D005260:Female; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D010063:Ovum / Q000276:immunology; D020545:Respiratory Mucosa / Q000276:immunology*; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000276:immunology*; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D007074:Immunoglobulin G; C505947:Tnfsf15 protein, mouse; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15; D014612:Vaccines